Northwest Biotherapeutics (DI) Announcements

Management and Board Change

12 August 2008 07:00:09



RNS Number : 1203B Northwest Biotherapeutics Inc 12 August 2008  
?
For Immediate Release
12 August 2008

Northwest Biotherapeutics
("NWBT" or the "Company")
Management and Board Change 
Northwest Biotherapeutics, Inc. (AIM: NWBS and NWBT; OTC BB: NWBO.US), announced that on August 12, 2008, Anthony P. Deasey resigned as Senior Vice President of Finance, Chief Financial Officer and ex officio Director of Northwest Biotherapeutics, Inc. (the "Company") in order to pursue a personal entrepreneurial opportunity.  
Day to day responsibilities related to the Company's accounting and financial administration will remain with the Company controller. Other financial functions, including pursuit of funding opportunities, will be carried out by the Company's Chief Executive Officer, Dr. Alton Boynton, and the Company's Chairperson, Ms. Linda Powers.  Although Mr. Deasey will discontinue his roles as an officer and ex officio director of the Company effective August 12, Mr. Deasey's employment with the Company will continue until September 30, 2008, to help facilitate the transition.  In addition, from October 1, 2008, through November 15, 2008, Mr. Deasey will provide part-time consulting services to the Company, and will receive consulting fees at a rate equal to 50% of his current monthly salary.
Dr. Alton Boynton, President and Chief Executive Officer commented: "We would like to thank Tony for his work at Northwest Biotherapeutics over the last year. We wish him well in his future entrepreneurial endeavours and are pleased to have him continue his services as a part-time consultant to the Company while he transitions to his new opportunity."  Mr. Deasey added, "I enjoyed working with the Northwest Biotherapeutics team, over the past year, to advance this exciting technology, and wish them continued success." 

For further information, please contact:

Northwest Biotherapeutics

Alton Boynton, President and Chief Executive Officer
+1 240-497-9024
Buchanan Communications

Lisa Baderoon (lisab@buchanan.uk.com) / Mary-Jane Johnson / Catherine Breen 
+44 (0)20 7466 5000
Collins Stewart

Adam Cowen/Tim Mickley
+44 (0)20 7523 8230
This information is provided by RNSThe company news service from the London Stock Exchange  END  BOAUUAVRWVRWARR

All data suppied by Digital Look (15 minute delay)




Risk Warning

There is an extra risk of losing money when shares are bought in some smaller companies including 'Penny Shares'. There is a big difference between the buying price and the selling price of these shares. If they have to be sold immediately, you may get back much less than you paid for them or you may have difficulty in selling them. Past performance is not a reliable indicator of future results. The price may change quickly and it may go down as well as up. You could lose every penny put into a particular share.

The information contained above has been compiled from documented sources which are believed to be reliable but, due to their very nature, are subject to a degree of historical inaccuracy and have not been independently verified and cannot be guaranteed. The pages on this website are provided for information only. City Equities Limited will not accept responsibility for loss incurred by any person or body acting, or refraining from acting, as a result of information and/or opinions given anywhere on this website. Issued by City Equities Limited, Aldermary House, 10-15 Queen Street, London, EC4N 1TY. Registered in England. Registered No. 2742847. Registered Address: Amwell House, 19 Amwell Street, Hoddeson, Herts. EN11 8TS. City Equities Limited is Authorised and regulated by the Financial Services Authority. Registration No. 155051.